Rex Bionics PLC Rex Bionics plays key role in Irving Caplan story
October 02 2014 - 2:00AM
RNS Non-Regulatory
TIDMRXB
Rex Bionics PLC
02 October 2014
2 October 2014
Rex Bionics plc
("Rex Bionics" or the "Company")
Rex Bionics is proud to have played a central role in the
extraordinary story of Irving Caplan
Rex Bionics plc (AIM: RXB), the developer and manufacturer of
REX products: hands-free robotic exoskeletons for use by wheelchair
users, is honoured to have been able to help Irving Caplan, a
tetraplegic father, to walk 30 steps across the dance floor to give
a speech at his daughter's wedding.
Irving was cycling to work in 2012 when he collided with a lorry
in Edgware, North London. He broke three vertebrae and spent 12
days in intensive care before being told he would never be able to
walk again and would instead be reliant upon a wheelchair for the
rest of his life. Attending an exhibition for people with
disabilities, Rex Bionics arranged to loan Irving a REX for the
wedding.
The story of Irving who, with the help of a REX, was able to
stand up and walk 30 steps at daughter Joanne's wedding, generated
significant media interest. The story featured in several prominent
international newspapers and radio broadcasts including BBC News,
The Daily Telegraph, The Times, The Sunday Times, Mail Online, The
Mirror, London Evening Standard, BBC Radio 4 and BBC Radio 5
Live.
The publicity surrounding Mr. Caplan's achievement follows
several other high profile news items and TV appearances about REX
and its ability to allow those who have lost their mobility to
stand and walk again.
Jeremy Curnock Cook, Chief Executive of Rex Bionics, commented:
"The story of Irving's triumph over his disability to share in the
most emotional moment of his daughter's life has captured the
public imagination and is an inspiration to people with mobility
impairments. Rex Bionics is proud to have played a part in enabling
Irving to fulfil his dream, and thrilled to see such widespread
interest."
Irving's story is an example of how REX is helping people with
mobility impairments carry out activities without the use of
crutches or walking frames to support them. Rex Bionics looks
forward to finding other opportunities to help people carry out
many different activities while gaining the benefits of being
upright in a standing position.
---
For further information please contact:
Rex Bionics Plc
Jeremy Curnock Cook, Chief Executive Officer
+44 (0) 781 086 6386
Peter Worrall, Chief Financial Officer
+44 (0)1428 645416
Oriel Securities Limited (NOMAD and Broker)
Juliet Thompson/Jonathan Senior
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Jessica Hodgson / Lindsey
Neville
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
About Rex Bionics
Rex Bionics (AIM: RXB) is an AIM-listed developer and
manufacturer of REX products, hands-free robotic exoskeletons for
use by people with mobility impairments. Founded in Auckland, New
Zealand by two robotics engineers with first-hand experience of
wheelchair users and their needs, Rex Bionics focuses on products
designed to enable wheelchair users to stand and walk autonomously
without the need for crutches or supports and is the only company
to produce hands-free walking devices for wheelchair users. Rex
Bionics' marketed products: REX Rehab and REX Personal, can be used
by people with complete spinal cord injury, but also by a much
broader potential customer base, including people with multiple
sclerosis and muscular dystrophy. In May 2014, Rex Bionics joined
AIM with a fundraising of GBP10 million (gross) to scale up
production, distribution and marketing internationally, in order to
support growing demand for both REX products as well as developing
the next generation of REX devices, REX 3.
For more information please visit, www.rexbionics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFEEIILLIIS
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Oct 2024 to Nov 2024
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Nov 2023 to Nov 2024